Tales Of Three Medical Device Markets In China
For device companies, China is proving to be a market replete with both immediate opportunity and significant risk. Here are several examples of how large device players are attempting to navigate this challenging new environment.
You may also be interested in...
Last month Medtronic agreed to pay close to $800 million for Chinese orthopedics implant maker China Kanghui Holdings. To be sure, the purchase of Kanghui secures Medtronic’s footing in China, one of the fastest growing health care economies in the world. In addition, it likely will help Medtronic close in on its goal of bringing in 20% of its revenue from emerging markets.
China Kanghui has emerged as one of the leaders in China’s orthopedics industry, building a business first on trauma and, more recently, spine. Now, with a pending move into reconstruction, the company is looking to other emerging markets, and eventually the US and Europe.
Santhera Pharmaceuticals’ vamorolone for treating Duchenne muscular dystrophy is among the latest medicines that have been submitted for review for potential pan-EU approval.